Insights on the Multiple Sclerosis Therapeutics Global Market to 2027 - Rising Funding for Multiple Sclerosis Research is Driving Growth - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Multiple Sclerosis Therapeutics Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Drug Class, Route of Administration, and Distribution Channel, and Geography" report has been added to ResearchAndMarkets.com's offering.
According to this report the global multiple sclerosis therapeutics market is expected to reach US$ 39,223.59 million by 2027 from US$ 24,026.90 million in 2019. The market is estimated to grow at a CAGR of 6.5% from 2020 to 2027. The report highlights trends prevailing in the market, and drivers and hindrances pertaining to the market growth.
Based on drug class, the market is segmented into immunosuppressant and immunomodulators. In 2019, the immunomodulators segment accounted for larger share of the market. Growth of this segment is attributed to launch of new generic drugs and increase in adoption of immunomodulators in multiple sclerosis (MS) treatment. The immunosuppressant segment is likely to register higher CAGR during the forecast period.
Based on route of administration, the multiple sclerosis therapeutics market is segmented into injectable and oral. The injectable segment held larger share of the market in 2019, and same segment is anticipated to register higher CAGR during the forecast period.
Based on distribution channel, the multiple sclerosis therapeutics market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment held the largest share of the market in 2019, and the e-commerce segment is anticipated to register the highest CAGR in the market during the forecast period.
COVID-19 pandemic has become the most significant challenge across the world. This would be difficult, especially for developing countries across the globe, as it may lead to reduction in imports due to disruptions in global trade. Till date, no definitive treatment against COVID-19 has been established. Patients with severe health conditions, such as neurological diseases, are witnessing delays in treatment. Supply chain disruptions associated with this pandemic situation would ultimately affect the sales of products for a short period. However, the supply of MS drugs has been continuous in the pandemic as pharmacies are allowed to stay open during the lockdown. Several companies are cutting their clinical trial activities and delaying product launches in response to the COVID-19 pandemic. For instance, Bristol-Myers Squibb delayed the launch of its multiple-sclerosis drug Zeposia (ozanimod) due to the COVID-19 pandemic.
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Multiple Sclerosis Therapeutics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the global Multiple Sclerosis Therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
- Growing Prevalence of Multiple Sclerosis (MS)
- Rising Funding for Multiple Sclerosis Research
- High Cost of Multiple Sclerosis Treatment
- Increasing Awareness About Multiple Sclerosis
- Development and Launch of Innovative Products
- Merck & Co., Inc.
- Novartis AG
- Bayer AG
- Bristol-Myers Squibb Company
- Horizon Therapeutics plc.
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- Takeda Pharmaceutical Company Limited
- F. HOFFMANN-LA ROCHE LTD.
For more information about this report visit https://www.researchandmarkets.com/r/e5v3hm
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900